ID   SK-MEL-23
AC   CVCL_6027
SY   SK-Mel-23; SK-Mel 23; SK-mel-23; SK MEL 23; SK Mel 23; Sk Mel23; SKMEL-23; SKMEL23; SKmel23; SK23-MEL; SK23-mel; SK23; AP-Mel
DR   BTO; BTO:0005333
DR   EFO; EFO_0006490
DR   BioSample; SAMN03470872
DR   BioSample; SAMN03473194
DR   cancercelllines; CVCL_6027
DR   CGH-DB; 9318-4
DR   Cosmic; 706107
DR   Cosmic; 721823
DR   Cosmic; 851051
DR   Cosmic; 876705
DR   Cosmic; 888852
DR   Cosmic; 897493
DR   Cosmic; 905231
DR   Cosmic; 1060423
DR   Cosmic; 1303054
DR   Cosmic; 1507594
DR   Cosmic; 1669139
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM206542
DR   GEO; GSM784516
DR   Lonza; 1343
DR   PharmacoDB; SK23_1416_2019
DR   Progenetix; CVCL_6027
DR   Wikidata; Q54953937
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   Patent=US4591572;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=978138;
RX   PubMed=1067619;
RX   PubMed=3518877;
RX   PubMed=6197381;
RX   PubMed=6582512;
RX   PubMed=6864164;
RX   PubMed=6933476;
RX   PubMed=7175440;
RX   PubMed=7509835;
RX   PubMed=7646526;
RX   PubMed=9670966;
RX   PubMed=9692547;
RX   PubMed=10766161;
RX   PubMed=15009714;
RX   PubMed=15467732;
RX   PubMed=17308088;
RX   PubMed=21725359;
RX   PubMed=22178978;
RX   PubMed=24576830;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Characteristics: Very highly pigmented.
CC   HLA typing: A*01,02:01; B*07,08 (PubMed=9670966).
CC   HLA typing: A*01:01,02:01; B*08:01,37:04; C*07:01,07:01 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10766161; PubMed=15009714).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 14,21
ST   D21S11: 26,29
ST   D2S1338: 20,25
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 10,11
ST   FGA: 18,22,23
ST   Penta D: 9.1,11,12
ST   Penta E: 12
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   Patent=US4591572;
RA   Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.;
RT   "Pigmentation associated, differentiation antigen of human melanoma
RT   and autologous antibody.";
RL   Patent number US4591572, 27-May-1986.
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=978138; DOI=10.1084/jem.144.4.873;
RA   Shiku H., Takahashi T., Oettgen H.F., Old L.J.;
RT   "Cell surface antigens of human malignant melanoma. II. Serological
RT   typing with immune adherence assays and definition of two new surface
RT   antigens.";
RL   J. Exp. Med. 144:873-881(1976).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6197381; DOI=10.1002/ijc.2910320610;
RA   Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.;
RT   "A pigmentation-associated, differentiation antigen of human melanoma
RT   defined by a precipitating antibody in human serum.";
RL   Int. J. Cancer 32:717-721(1983).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=7175440; DOI=10.1084/jem.156.6.1755;
RA   Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.;
RT   "Surface antigens of melanocytes and melanomas. Markers of melanocyte
RT   differentiation and melanoma subsets.";
RL   J. Exp. Med. 156:1755-1766(1982).
//
RX   PubMed=7509835; DOI=10.1111/1523-1747.ep12371784;
RA   Bouchard B., Vijayasaradhi S., Houghton A.N.;
RT   "Production and characterization of antibodies against human
RT   tyrosinase.";
RL   J. Invest. Dermatol. 102:291-295(1994).
//
RX   PubMed=7646526; DOI=10.1006/bbrc.1995.2187;
RA   Artuc M., Nurnberg W., Czarnetzki B.M., Schadendorf D.;
RT   "Characterization of gene regulatory elements for selective gene
RT   expression in human melanoma cells.";
RL   Biochem. Biophys. Res. Commun. 213:699-705(1995).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=9692547; DOI=10.1038/sj.onc.1201881;
RA   Tsao H., Zhang X., Benoit E., Haluska F.G.;
RT   "Identification of PTEN/MMAC1 alterations in uncultured melanomas and
RT   melanoma cell lines.";
RL   Oncogene 16:3397-3402(1998).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=22178978; DOI=10.1016/j.freeradbiomed.2011.11.019;
RA   Swalwell H., Latimer J., Haywood R.M., Birch-Machin M.A.;
RT   "Investigating the role of melanin in UVA/UVB- and hydrogen
RT   peroxide-induced cellular and mitochondrial ROS production and
RT   mitochondrial DNA damage in human melanoma cells.";
RL   Free Radic. Biol. Med. 52:626-634(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//